Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF in Chronic Hepatitis B with Decompensated Liver Disease
NCT04683341Phase 4
Key facts
- Status
- Unknown
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Countries
- 1
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Conditions
- Chronic Hepatitis B (CHB)
01
Overview
Phase 4, open-label trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Primary endpoint: Complete virological suppression at 48 weeks. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-label
03
Who it enrols
Adults with chronic HBV infection and hepatic decompensation (CTP score >= 7 or portal hypertension complications), excluding those with MELD >= 30, HCC, or severe comorbidities.
04
Endpoints
Primary
Complete virological suppression
Beyond the preview
Go deeper on NCT04683341.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683341.